135 related articles for article (PubMed ID: 33830229)
1. Quality of Preventive and Chronic Illness Care for Insured Adults With Opioid Use Disorder.
Anderson KE; Alexander GC; Niles L; Scholle SH; Saloner B; Dy SM
JAMA Netw Open; 2021 Apr; 4(4):e214925. PubMed ID: 33830229
[TBL] [Abstract][Full Text] [Related]
2. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.
Wakeman SE; Larochelle MR; Ameli O; Chaisson CE; McPheeters JT; Crown WH; Azocar F; Sanghavi DM
JAMA Netw Open; 2020 Feb; 3(2):e1920622. PubMed ID: 32022884
[TBL] [Abstract][Full Text] [Related]
3. Quality of Buprenorphine Care for Insured Adults With Opioid Use Disorder.
Anderson KE; Saloner B; Eckstein J; Chaisson CE; Scholle SH; Niles L; Dy S; Alexander GC
Med Care; 2021 May; 59(5):393-401. PubMed ID: 33734194
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and treatment of opioid use disorders among primary care patients in six health systems.
Lapham G; Boudreau DM; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Samet JH; Saxon AJ; Campbell CI; Glass JE; Rossom RC; Murphy MT; Binswanger IA; Yarborough BJH; Bradley KA;
Drug Alcohol Depend; 2020 Feb; 207():107732. PubMed ID: 31835068
[TBL] [Abstract][Full Text] [Related]
5. Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001-2014.
Hadland SE; Wharam JF; Schuster MA; Zhang F; Samet JH; Larochelle MR
JAMA Pediatr; 2017 Aug; 171(8):747-755. PubMed ID: 28628701
[TBL] [Abstract][Full Text] [Related]
6. Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019.
Mauro PM; Gutkind S; Annunziato EM; Samples H
JAMA Netw Open; 2022 Mar; 5(3):e223821. PubMed ID: 35319762
[TBL] [Abstract][Full Text] [Related]
7. Telemedicine Use and Quality of Opioid Use Disorder Treatment in the US During the COVID-19 Pandemic.
Hailu R; Mehrotra A; Huskamp HA; Busch AB; Barnett ML
JAMA Netw Open; 2023 Jan; 6(1):e2252381. PubMed ID: 36692880
[TBL] [Abstract][Full Text] [Related]
8. Disparities in United States hospitalizations for serious infections in patients with and without opioid use disorder: A nationwide observational study.
Kim JH; Fine DR; Li L; Kimmel SD; Ngo LH; Suzuki J; Price CN; Ronan MV; Herzig SJ
PLoS Med; 2020 Aug; 17(8):e1003247. PubMed ID: 32764761
[TBL] [Abstract][Full Text] [Related]
9. Discharge locations after hospitalizations involving opioid use disorder among medicare beneficiaries.
Moyo P; Eliot M; Shah A; Goodyear K; Jutkowitz E; Thomas K; Zullo AR
Addict Sci Clin Pract; 2022 Oct; 17(1):57. PubMed ID: 36209151
[TBL] [Abstract][Full Text] [Related]
10. Associations between Medication Assisted Therapy Services Delivery and Mortality in a National Cohort of Veterans with Posttraumatic Stress Disorder and Opioid Use Disorder.
Riblet NB; Gottlieb DJ; Shiner B; Cornelius SL; Watts BV
J Dual Diagn; 2020; 16(2):228-238. PubMed ID: 31852392
[No Abstract] [Full Text] [Related]
11. Association of Criminal Statutes for Opioid Use Disorder With Prevalence and Treatment Among Pregnant Women With Commercial Insurance in the United States.
Gressler LE; Shah S; Shaya FT
JAMA Netw Open; 2019 Mar; 2(3):e190338. PubMed ID: 30848807
[TBL] [Abstract][Full Text] [Related]
12. Association Between Opioid Tapering and Subsequent Health Care Use, Medication Adherence, and Chronic Condition Control.
Magnan EM; Tancredi DJ; Xing G; Agnoli A; Jerant A; Fenton JJ
JAMA Netw Open; 2023 Feb; 6(2):e2255101. PubMed ID: 36749586
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of US Counties With High Opioid Overdose Mortality and Low Capacity to Deliver Medications for Opioid Use Disorder.
Haffajee RL; Lin LA; Bohnert ASB; Goldstick JE
JAMA Netw Open; 2019 Jun; 2(6):e196373. PubMed ID: 31251376
[TBL] [Abstract][Full Text] [Related]
14. Characteristics and treatment patterns of US commercially insured and Medicaid patients with opioid dependence or abuse.
Wollschlaeger BA; Willson TM; Montejano LB; Ronquest NA; Nadipelli VR
J Opioid Manag; 2017; 13(4):207-220. PubMed ID: 28953313
[TBL] [Abstract][Full Text] [Related]
15. Trends in Urine Drug Monitoring Among Persons Receiving Long-Term Opioids and Persons with Opioid Use Disorder in the United States.
Sohn M; Talbert JC; Huang Z; Oser C; Freeman PR
Pain Physician; 2021 Mar; 24(2):E249-E256. PubMed ID: 33740362
[TBL] [Abstract][Full Text] [Related]
16. Utilization of treatment by Medicaid enrollees with opioid use disorder and co-occurring substance use disorders.
O'Brien P; Henke RM; Schaefer MB; Lin J; Creedon TB
Drug Alcohol Depend; 2020 Dec; 217():108261. PubMed ID: 32979735
[TBL] [Abstract][Full Text] [Related]
17. Correlates of specialty substance use treatment among adults with opioid use disorders.
Romo E; Ulbricht CM; Clark RE; Lapane KL
Addict Behav; 2018 Nov; 86():96-103. PubMed ID: 29551551
[TBL] [Abstract][Full Text] [Related]
18. Opioid Use Disorder Increases 30-Day Readmission Risk in Inflammatory Bowel Disease Hospitalizations: a Nationwide Matched Analysis.
Charilaou P; Mohapatra S; Joshi T; Devani K; Gadiparthi C; Pitchumoni CS; Goldstein D
J Crohns Colitis; 2020 Jun; 14(5):636-645. PubMed ID: 31804682
[TBL] [Abstract][Full Text] [Related]
19. Association of Opioid Use Disorder Treatment With Alcohol-Related Acute Events.
Xu KY; Presnall N; Mintz CM; Borodovsky JT; Bhat NR; Bierut LJ; Grucza RA
JAMA Netw Open; 2021 Feb; 4(2):e210061. PubMed ID: 33625511
[TBL] [Abstract][Full Text] [Related]
20. Behavioral health treatment utilization among individuals with co-occurring opioid use disorder and mental illness: Evidence from a national survey.
Novak P; Feder KA; Ali MM; Chen J
J Subst Abuse Treat; 2019 Mar; 98():47-52. PubMed ID: 30665603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
